Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36107723)

  • 1. Peritoneal carcinomatosis with intraperitoneal immunotherapy: current treatment options and perspectives.
    Wei GX; Du Y; Zhou YW; Li LJ; Qiu M
    Expert Rev Gastroenterol Hepatol; 2022 Sep; 16(9):851-861. PubMed ID: 36107723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The current status of immunotherapy in peritoneal carcinomatosis.
    Ströhlein MA; Heiss MM; Jauch KW
    Expert Rev Anticancer Ther; 2016 Oct; 16(10):1019-27. PubMed ID: 27530056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes.
    Ornella MSC; Badrinath N; Kim KA; Kim JH; Cho E; Hwang TH; Kim JJ
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab.
    Goéré D; Gras-Chaput N; Aupérin A; Flament C; Mariette C; Glehen O; Zitvogel L; Elias D
    BMC Cancer; 2014 Mar; 14():148. PubMed ID: 24589307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer.
    Lee YS; Lee WS; Kim CW; Lee SJ; Yang H; Kong SJ; Ning J; Yang KM; Kang B; Kim WR; Chon HJ; Kim C
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33199510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraperitoneal immunotherapy: historical perspectives and modern therapy.
    Morano WF; Aggarwal A; Love P; Richard SD; Esquivel J; Bowne WB
    Cancer Gene Ther; 2016 Nov; 23(11):373-381. PubMed ID: 27834358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraperitoneal administration of carcinoembryonic antigen-directed chimeric antigen receptor T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal cancer in pre-clinical study.
    Qian S; Chen J; Zhao Y; Zhu X; Dai D; Qin L; Hong J; Xu Y; Yang Z; Li Y; Guijo I; Jiménez-Galanes S; Guadalajara H; García-Arranz M; García-Olmo D; Shen J; Villarejo-Campos P; Qian C
    Cytotherapy; 2024 Feb; 26(2):113-125. PubMed ID: 37999667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rationale.
    Roviello F; Caruso S; Neri A; Marrelli D
    Eur J Surg Oncol; 2013 Dec; 39(12):1309-16. PubMed ID: 24183797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
    de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
    BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer.
    Lee SJ; Yang H; Kim WR; Lee YS; Lee WS; Kong SJ; Lee HJ; Kim JH; Cheon J; Kang B; Chon HJ; Kim C
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34145029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peritoneal carcinomatosis arising from rectal or colonic adenocarcinoma treated with cytoreductive surgery (CRS) hyperthermic intraperitoneal chemotherapy (HIPEC): two different diseases.
    Tonello M; Ortega-Perez G; Alonso-Casado O; Torres-Mesa P; Guiñez G; Gonzalez-Moreno S
    Clin Transl Oncol; 2018 Oct; 20(10):1268-1273. PubMed ID: 29667123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peritoneal carcinomatosis from unusual cancer origins: Is there a role for hyperthermic intraperitoneal chemotherapy?
    Honoré C; Goéré D; Macovei R; Colace L; Benhaim L; Elias D
    J Visc Surg; 2016 Apr; 153(2):101-7. PubMed ID: 26698380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of CAR-T Cells in Peritoneal Carcinomatosis from Gastric Cancer: Rationale, Experimental Work, and Clinical Applications.
    Qian S; Villarejo-Campos P; García-Olmo D
    J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal chemotherapy against peritoneal carcinomatosis: current status and future perspective.
    Kitayama J
    Surg Oncol; 2014 Jun; 23(2):99-106. PubMed ID: 24721661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies.
    Koppe MJ; Boerman OC; Oyen WJ; Bleichrodt RP
    Ann Surg; 2006 Feb; 243(2):212-22. PubMed ID: 16432354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery.
    Katz SC; Point GR; Cunetta M; Thorn M; Guha P; Espat NJ; Boutros C; Hanna N; Junghans RP
    Cancer Gene Ther; 2016 May; 23(5):142-8. PubMed ID: 27080226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal immunotherapy to prevent peritoneal carcinomatosis in patients with advanced gastrointestinal malignancies.
    Ströhlein MA; Heiss MM
    J Surg Oncol; 2009 Sep; 100(4):329-30. PubMed ID: 19697440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial.
    Klaver CE; Musters GD; Bemelman WA; Punt CJ; Verwaal VJ; Dijkgraaf MG; Aalbers AG; van der Bilt JD; Boerma D; Bremers AJ; Burger JW; Buskens CJ; Evers P; van Ginkel RJ; van Grevenstein WM; Hemmer PH; de Hingh IH; Lammers LA; van Leeuwen BL; Meijerink WJ; Nienhuijs SW; Pon J; Radema SA; van Ramshorst B; Snaebjornsson P; Tuynman JB; Te Velde EA; Wiezer MJ; de Wilt JH; Tanis PJ
    BMC Cancer; 2015 May; 15():428. PubMed ID: 26003804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraperitoneal CMP-001: A Novel Immunotherapy for Treating Peritoneal Carcinomatosis of Gastrointestinal and Pancreaticobiliary Cancer.
    Miller AM; Lemke-Miltner CD; Blackwell S; Tomanek-Chalkley A; Gibson-Corely KN; Coleman KL; Weiner GJ; Chan CHF
    Ann Surg Oncol; 2021 Feb; 28(2):1187-1197. PubMed ID: 32409965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years.
    Vaira M; Cioppa T; D'Amico S; de Marco G; D'Alessandro M; Fiorentini G; De Simone M
    In Vivo; 2010; 24(1):79-84. PubMed ID: 20133981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.